scholarly journals Tacrolimus-induced bilateral optic neuropathy: A case report

2021 ◽  
pp. 4-4
Author(s):  
Lepsa Zoric ◽  
Aleksandra Ilic ◽  
Emina Colak ◽  
Milos Mirkovic ◽  
Jelica Pantelic ◽  
...  
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Optic Neuropathy ◽  
Vision Loss ◽  
White Male ◽  
Immunosuppressive Drug ◽  
Organ Rejection ◽  
Toxic Optic Neuropathy ◽  
Tacrolimus Therapy ◽  
Male Patients

Intrduction. Tacrolimus (fujimycin or FK506) is a potent immunosuppressive drug with growing usage. It is usually used in prevention of transplanted organ rejection. Its use is highly valuable, but like other immunosupressants, it has adverse effects. One of them is optic neuropathy. Case report. A 47-year-old white male patients who had received tacrolimus therapy for nine years, after kidney transplantation, developed a subacute, painless vision loss on both eyes. He was thoroughly examined on different possible optic neuropathies and other causes of vision loss. After exclusion of other possible causes, the diagnosis of toxic optic neuropathy was established. His therapy was converted to cyclosporine, by his nephrologist, but his vision had improved only slightly. Conclusion. Toxic optic neuropathies are presented in everyday ophthalmological practice, but they are underestimated. Diagnosis can be demanding, especially when it comes to drugs and substances whose possible toxic effect on the optic nerve is not widely known. Unlike other adverse effects of tacrolimus therapy on nervous system, optic neuropathy can causes great and permanent functional impairment.

scholarly journals Ethambutol toxic optic neuropathy: A case report and review

2018 ◽  
Vol 77 (1) ◽  
Author(s):  
Kevin C. Phillips ◽  
Peter C. Clarke-Farr
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Optic Neuropathy ◽  
Vision Loss ◽  
Early Recognition ◽  
Treatment Cessation ◽  
Toxic Optic Neuropathy ◽  
Vision Restoration

This article presents a case of ethambutol toxic optic neuropathy determined during the routine optometric examination of a 66-year-old man. Ethambutol is an established drug for the treatment of tuberculosis, but has significant side effects, notably optic neuropathy. The prognosis for vision restoration is unpredictable, with the possibility of permanent vision loss. Treatment cessation is the only option to limit ocular damage; therefore, the early recognition of ethambutol optic neuropathy by optometrists is essential.

Vision loss following denileukin diftitox treatment: A case report of possible posterior ischemic optic neuropathy

2007 ◽  
Vol 48 (4) ◽  
pp. 808-811 ◽  
Author(s):  
Meyeon Park ◽  
Grant T. Liu ◽  
Jody Piltz-Seymour ◽  
Catherine L. Wisda ◽  
Alain H. Rook ◽  
...  
Keyword(s):  
Case Report ◽  
Optic Neuropathy ◽  
Vision Loss ◽  
Ischemic Optic Neuropathy ◽  
Denileukin Diftitox ◽  
Posterior Ischemic Optic Neuropathy

scholarly journals Loss of vision secondary to toxic optic neuropathy due to gutka overdose: A Case Report

2021 ◽  
Vol 11 (5) ◽  
pp. 139-140
Author(s):  
Irfan Kabiruddin Jeeva ◽  
 Sidra Masud ◽  
Syed Hasan Raza Abidi, ◽  
Tazeen Saeed Ali ◽  
Ayesha Akbar Waheed, ◽  
...  
Keyword(s):  
Case Report ◽  
Optic Nerve ◽  
Optic Neuropathy ◽  
Liver Function Tests ◽  
Nerve Fibers ◽  
Central Scotoma ◽  
Case Presentation ◽  
Toxic Optic Neuropathy ◽  
Oral Form ◽  
History Of

Introduction: Toxic optic neuropathy is defined as the damage caused by a toxin to the optic nerve fibers. There is a vast list of toxins that may lead to optic neuropathies. One of the toxins among this list is tobacco. Gutka being an oral form of tobacco, however, has not been previously related to optic neuropathy. Case presentation: We present a case of a 22-year-old male who presented with decreased far vision and gradually increasing photophobia. He had a history of gutka usage, a form of smokeless tobacco. Investigations revealed a central scotoma on FOV, a swollen optic disc on OCT and deranged Liver function tests. A diagnosis of RIGHT + LEFT optic neuropathy secondary to a chemical toxic was made, which in this case, was gutka. Conclusion: Consumption of gutka can lead to irreversible toxic optic neuropathy.

Optic atrophy after cabazitaxel treatment in a patient with castration-resistant prostate cancer: a case report

2018 ◽  
Vol 64 (2) ◽  
pp. 71-73 ◽  
Author(s):  
Sevda Diker ◽  
Ömer Diker
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Case Report ◽  
Adverse Effects ◽  
Optic Neuropathy ◽  
Optic Atrophy ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Anti Cancer ◽  
New Generation

Taxanes are a group of cytotoxic anti-cancer agents used in the treatment of solid tumours. The neurotoxic adverse effects of docetaxel and paclitaxel, including optic neuropathy, are well known. Cabazitaxel is a new generation taxane showing lesser drug resistance when compared with previous ones. Optic atrophy due to the use of cabazitaxel has not been previously reported. Herein, we report a patient with prostate cancer who developed optic atrophy after cabazitaxel treatment.

scholarly journals Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report

2019 ◽  
Author(s):  
Bogdan Augustin Chis ◽  
Cristina Nicula ◽  
Dan Dumitrascu
Keyword(s):  
Case Report ◽  
Hepatitis C ◽  
Adverse Effects ◽  
Viral Hepatitis ◽  
Optic Neuropathy ◽  
Standard Of Care ◽  
Low Grade ◽  
Blurred Vision ◽  
Viral Hepatitis C ◽  
Ifn Treatment

Introduction. Hepatitis C viral infection (HCV) represents an important health problem worldwide. Natural evolution, with its complications, remains a high cause of mortality and morbidity. Interferon (IFN) treatment, along with ribavirin (RBV), was for several years the standard of care. However, many adverse effects have been described during this therapy. We report a very elusive case of optic neuropathy. Case report. We report the case of a female patient, 50 years old, who underwent pegylated IFN alfa 2B and RBV treatment for viral hepatitis C with low grade fibrosis, in a period when she was not qualified for free oral therapy (with direct acting agents according regulations in this country at that time). After 10 weeks of treatment, she experienced blurred vision and an optic neuropathy was diagnosed, attributed to the HCV. The symptoms and eye fundus alterations (hemorrhage, exudates) remitted after discontinuation of therapy. Conclusion. IFN treatment remains an option for viral hepatitis, but the adverse effects are to be considered. Optic neuropathy can occur during the former standard of care HCV therapy. Patients submitted to IFN plus RBV therapy should be monitored for ocular adverse effects.

scholarly journals Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Thomas P Moloney ◽  
Wen Xu ◽  
Kristopher Rallah-Baker ◽  
Niara Oliveira ◽  
Natasha Woodward ◽  
...  
Keyword(s):  
Case Report ◽  
Optic Neuropathy ◽  
Toxic Optic Neuropathy ◽  
Docetaxel Chemotherapy

scholarly journals Unilateral Blurred Vision as the Sole Presenting Symptom of Chronic Lymphocytic Leukemia

2020 ◽  
Author(s):  
Rajesh K. Sharma ◽  
Kevin Mays
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Optic Neuropathy ◽  
Vision Loss ◽  
White Male ◽  
Lymphocytic Leukemia ◽  
Fiber Layer ◽  
Blurred Vision ◽  
Optic Disc Swelling ◽  
Blurry Vision ◽  
Eye Examination

Purpose: To describe a case of infiltrative optic neuropathy caused by chronic lymphocytic leukemia. Case Report: A 41-year-old white male presented with painless, blurry vision in the left eye. Examination revealed unilateral optic nerve swelling confirmed by optical coherence tomography (OCT). Initial workup revealed mild leukocytosis, eventually diagnosed as chronic lymphocytic leukemia (CLL). No other cause of optic neuropathy was identified despite extensive investigation. The patient developed rapidly progressive retinal ganglion cell nerve fiber layer (NFL) atrophy and relative afferent pupillary defect (RAPD) of the left eye despite steroid treatment but stabilized after four cycles of CLLtargeted chemotherapy. Although infiltrative optic neuropathy is well-known in leukemia, presentation with only subtle vision loss is rare. Vision loss usually presents late in leukemic infiltrative optic neuropathy and therefore must be considered in patients with optic disc swelling and leukocytosis. Conclusion: When treating CLL, progressive visual decline with coexistent optic neuropathy may warrant chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document